Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Negative
STE
STERIS plcNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$21.90B
P/E Ratio
27.46
EPS
$8.18
Beta
0.91
52W High
$267.14
52W Low
$193.97
50-Day MA
$225.32
200-Day MA
$232.88
Dividend Yield
1.11%
Profit Margin
13.30%
Forward P/E
20.79
PEG Ratio
1.89
About STERIS plc
Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.
Fundamentals
| Revenue (TTM) | $6.04B |
| Gross Profit (TTM) | $2.68B |
| EBITDA | $1.64B |
| Operating Margin | 19.20% |
| Return on Equity | 11.40% |
| Return on Assets | 6.80% |
| Revenue/Share (TTM) | $61.61 |
| Book Value | $73.92 |
| Price-to-Book | 3.07 |
| Price-to-Sales (TTM) | 3.63 |
| EV/Revenue | 3.922 |
| EV/EBITDA | 14.43 |
| Quarterly Earnings Growth (YoY) | 14.00% |
| Quarterly Revenue Growth (YoY) | 7.30% |
| Shares Outstanding | $97.50M |
| Float | $97.08M |
| % Insiders | 0.31% |
| % Institutions | 101.05% |
Historical Volatility
HV 10-Day
11.81%
HV 20-Day
15.19%
HV 30-Day
24.19%
HV 60-Day
27.64%
HV Rank
40.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($263.12 target)
3
Strong Buy4
Buy2
HoldLatest News
STERIS to Present at the Morgan Stanley Healthcare Conference
Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.
GlobeNewsWire9/1/2026Neutral
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
Zacks Investment Research8/21/2026Positive
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
Zacks Investment Research8/20/2026Positive
STERIS plc (STE) Q1 2027 Earnings Call Transcript
STERIS plc (STE) Q1 2027 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
Zacks Investment Research8/6/2026Neutral
5 Quality Stocks Set to Reward Investors With Dividend Hikes
Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.
Zacks Investment Research8/6/2026Positive
STERIS Announces Financial Results for Fiscal 2027 First Quarter
DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic revenue growth was 6% in the first quarter.
GlobeNewsWire8/5/2026Neutral
STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries
GlobeNewsWire8/5/2026Neutral
STERIS Raises Dividend to $0.69 per share
DUBLIN, IRELAND, July 30, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.69 per share. This represents a $0.06 increase in the dividend and the Company's 21st consecutive year of dividend growth. The dividend is payable on September 25, 2026, to shareholders of record at the close of business on September 4, 2026.
GlobeNewsWire7/30/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STE and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/8/2026